Clinical Trial Update: A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating safety, immunogenicity, and optimal dosing of a new Shigella vaccine in Kenyan infants has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Shigellosis

Drugs mentioned

• Shigella vaccine candidate

Snippet

Sponsor: LimmaTech Biologics AG | Conditions: Shigellosis | Phase 1, Phase 2 | Status: COMPLETED